Deans' stroke musings: Biopharmaceutical companies have 215 heart disease/stroke drugs in R&D pipeline

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, June 21, 2013

Biopharmaceutical companies have 215 heart disease/stroke drugs in R&D pipeline

Your doctor better be following up with these to see which may be useful for you. And if your doctor was any good they would be participating in these trials. How the hell else do you think stroke drugs are going to be evaluated?
http://www.lexology.com/library/detail.aspx?g=b66d5428-b2b4-4593-9bc4-e082f4309d45
According to a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, U.S. biopharmaceutical companies have 215 medicines under development for the treatment of heart disease and stroke. The medicines, which are currently either in human clinical trials or undergoing U.S. Food and Drug Administration review, aim to treat or prevent these two leading causes of death in the United States by addressing heart failure, lipid disorders, stroke, and hypertension. PhRMA President and CEO John Castellani noted that many of these pipeline drugs use cutting-edge technologies including gene therapy and genetic engineering. He said, “These promising new approaches offer great hope to better prevent and treat heart diseases. They also hold the potential of helping to control costs within our healthcare system, as reflected in a growing body of evidence showing that medicines— including those for heart disease—can help control overall healthcare costs.” See PhRMA Press Release, June 12, 2013.